Research Article

Related GMR Articles

Cisplatin; Inhibitory effect; Ovarian cancer; Signal transducer and activator of transcription 3 (STAT3)

The aim of the present study was to investigate the anti-ovarian cancer effect of the inhibitor of signal transducer and activator of transcription 3 (STAT3), WP1066. Western blot was used to detect the phosphorylation of STAT3 in ovarian cancer cell line SKOV3 and cisplatin-resistant ovarian cancer cell line SKOV3/DDP. MTT and colony-forming assays were performed to evaluate the ... more

Y.J. Tang; Z.L. Sun; W.G. Wu; J. Xing; Y.F. He; D.M. Xin; P. Han
Cisplatin; Immune response; Lactobacillus; Lung cancer

The intestinal microflora affects inflammation and immunity, not only locally at the mucosal level but also systemically, raising the question of whether the microflora affects inflammatory processes that contribute to cancer and its therapy. Prebiotics have also been found to play an antitumor role that is not limited to the gut. We investigated the antitumor roles of the intestinal ... more

Q.F. Gui; H.F. Lu; C.X. Zhang; Z.R. Xu; Y.H. Yang
Antigenotoxicity; Antimutagenicity; Cisplatin

Cisplatin is an effective antineoplastic drug. However, it provokes considerable collateral effects, including genotoxic and clastogenic activity. It has been reported that a diet rich in glutamine can help inhibit such collateral effects. We evaluated this activity in 40 Swiss mice, distributed into eight experimental groups: G1 - Control group (PBS 0.1 mL/10g body weight); G2 - ... more

R.J. Oliveira; E.S. Sassaki; A.C.D. Monreal; M.T.F.D. Monreal; J.R. Pesarini; M.O. Mauro; R. Matuo; A.F. Silva; N.N. Zobiole; J.M. Siqueira; L.R. Ribeiro; M.S. Mantovani
Cisplatin; Histone deacetylase inhibitor; Malignant pleural mesothelioma; Panobinostat

New therapeutic approaches are still needed for effective malignant pleural mesothelioma treatment. The use of classical chemotherapy agents in combination with newly developed molecules may shed light on new therapeutic approaches. We aimed to determine the efficacy of panobinostat, alone and in combination with cisplatin, on cell survival and mRNA expression of FOXO3A, ... more

K.E. Gultekin; M.K. Yurdakonar; E. Yaman; U.S. Yuce; A. Yilmaz; E. Alp; A. Celik; S.M. Demiroz; H.I. Onen
Azithromycin; Chlamydia pneumoniae; Cisplatin; Non-small cell lung cancer (NSCLC); Paclitaxel

Although new chemotherapeutic drugs have been applied constantly, their efficacy for non-small cell lung cancer (NSCLC) is still not satisfactory. In recent years, epidemiological investigations have shown that lung cancer may be induced by chronic Chlamydia pneumoniae (Cpn) infection, since stable high titers of Cpn antibodies, especially IgA, are a hallmark of chronic ... more

D.J. Chu; D.E. Yao; Y.F. Zhuang; Y. Hong; X.C. Zhu; Z.R. Fang; J. Yu; Z.Y. Yu
genomic instability; LOH; MSI; Ovarian cancer

Ovarian cancer is currently the most lethal gynecological malignancy in women. It is a heterogeneous and cytogenetically complex disease previously associated with genomic instability. Our purpose was to analyze microsatellite markers to determine patterns and levels of instability as well as possible correlations with histopathological parameters. Polymerase chain reaction was used to ... more

L.N.R. Alves; E.V. Wolfgramm; A.Kde Castro Neto; I.D. Louro